INVESTINGMorning Bell With Jim Cramer: Buy Bristol-Myers, Not GileadBy Danny PetersonJun 30, 2020 10:28 AM EDT
PRESS RELEASESEuropean Commission Approves Reblozyl (luspatercept) For The Treatment Of Transfusion-Dependent Anemia In Adult Patients With Myelodysplastic Syndromes Or Beta ThalassemiaBy Business WireJun 26, 2020 9:05 AM EDT
PRESS RELEASESVidence, LLC Launched To Set Standard For High-Quality Cancer Data, Research And AnalyticsBy PR NewswireJun 18, 2020 2:11 PM EDT
PRESS RELEASESBristol Myers Squibb To Announce Results For Second Quarter 2020 On August 6, 2020By Business WireJun 18, 2020 6:59 AM EDT
PRESS RELEASESU.S. Food And Drug Administration Approves Opdivo® (nivolumab) For The Treatment Of Patients With Advanced Esophageal Squamous Cell Carcinoma (ESCC) After Prior Fluoropyrimidine- And Platinum-based ChemotherapyBy Business WireJun 10, 2020 7:52 PM EDT
PRESS RELEASESBristol Myers Squibb To Take Part In 41st Annual Goldman Sachs Global Healthcare ConferenceBy Business WireJun 4, 2020 6:59 AM EDT
PRESS RELEASESNew Data Reinforce Improved And Durable Clinical Responses Of Orencia In Moderate-to-Severe Early Rheumatoid Arthritis Patients With Autoantibodies Linked To More Severe DiseaseBy Business WireJun 3, 2020 6:59 AM EDT
INVESTINGBristol-Myers Squibb Colitis Drug Meets Late-Stage GoalsBy Rob LenihanJun 2, 2020 8:43 AM EDT
PRESS RELEASESBristol Myers Squibb Announces Positive Topline Results From Pivotal Phase 3 True North Trial Evaluating Zeposia (ozanimod) In Patients With Moderate To Severe Ulcerative ColitisBy Business WireJun 2, 2020 6:59 AM EDT
PRESS RELEASESBristol Myers Squibb Announces Commercial Launch And Availability Of ZEPOSIA® (ozanimod), A New Oral Treatment For Relapsing Forms Of Multiple SclerosisBy Business WireJun 1, 2020 6:59 AM EDT
PRESS RELEASESBristol Myers Squibb To Hold Virtual Three-Part Investor SeriesBy Business WireMay 29, 2020 6:59 AM EDT
JIM CRAMERNew Market: Cramer's 'Mad Money' Recap (Thursday 5/28/20)By Scott RuttMay 28, 2020 8:58 PM EDT
PRESS RELEASESBristol Myers Squibb Receives European Commission Approval For Zeposia (ozanimod) For The Treatment Of Adult Patients With Relapsing Remitting Multiple Sclerosis With Active DiseaseBy Business WireMay 27, 2020 6:59 AM EDT
PRESS RELEASESU.S. Food And Drug Administration Approves Opdivo® (nivolumab) Yervoy® (ipilimumab) Combined With Limited Chemotherapy As First-Line Treatment Of Metastatic Or Recurrent Non-Small Cell Lung CancerBy Business WireMay 26, 2020 5:48 PM EDT
PRESS RELEASESEuropean Medicines Agency Validates Bristol Myers Squibb's Applications For Idecabtagene Vicleucel (Ide-cel, Bb2121) And CC-486By Business WireMay 22, 2020 6:59 AM EDT
INVESTING10 Best Stocks in the S&P 500 Last Week: Buy Nvidia Stock?By Danny PetersonMay 18, 2020 10:35 AM EDT
JIM CRAMERWho Will Survive?: Cramer's 'Mad Money' Recap (Thursday 5/14/20)By Scott RuttMay 14, 2020 8:42 PM EDT
INVESTINGBristol-Myers to Resubmit Myeloma-Drug Bid to FDA - Here’s the TradeBy Richard SuttmeierMay 13, 2020 1:15 PM EDT
INVESTINGBristol-Myers, Bluebird Bio to Resubmit FDA Bid for Myeloma TreatmentBy Rob LenihanMay 13, 2020 10:41 AM EDT
PRESS RELEASESBristol Myers Squibb And Bluebird Bio Provide Regulatory Update On Idecabtagene Vicleucel (ide-cel, Bb2121) For The Treatment Of Patients With Multiple MyelomaBy Business WireMay 13, 2020 6:59 AM EDT
PRESS RELEASESGRYT Health And Bristol Myers Squibb Team Up To Launch COVID Advocacy Exchange For Patient AdvocatesBy PR NewswireMay 12, 2020 7:07 AM EDT
PRESS RELEASESBristol Myers Squibb To Take Part In The UBS Virtual Global Healthcare ConferenceBy Business WireMay 12, 2020 6:59 AM EDT
PRESS RELEASESGRYT Health And Bristol Myers Squibb Team Up To Launch COVID Advocacy Exchange For Patient AdvocatesBy Business WireMay 12, 2020 6:58 AM EDT
PRESS RELEASESBristol Myers Squibb Research At ASCO Demonstrates Diverse Approaches In Treating Cancer To Improve Outcomes For PatientsBy Business WireMay 11, 2020 6:59 AM EDT
